Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PMNP-Healthy Norms | Healthy Norms |
| |
| PMNP-Subclinical high-risk | Subclinical high-risk |
| |
| PMNP-Schizophrenia and Psychosis | Schizophrenia and Psychosis patient |
| |
| PMNP-MDD | major depressive disorder patient |
| |
| PMNP-ASD | autism spectrum disorder patient |
| |
| PMNP-BD | bipolar disorder patient |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids | Drug | Patients with mental disorders should take the appropriate medicine as prescribed by the doctor,and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors. |
| Measure | Description | Time Frame |
|---|---|---|
| cortical morphology | Data were obtained using magnetic resonance scans | 40 minutes |
| target gene charaacteristics | 10ml peripheral blood was extracted for gene analysis | 1 day |
| scale scores | The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results. | 90 minutes. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients from inpatient and outpatient the second Xiangya Hosptial of Central South University, Healthy controls from community, school and street recruitment
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yunzhi Pan | Contact | 15074818197 | panyunzhi@csu.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Second Xiangya hospital of central south univerity | Recruiting | Changsha | Hunan | 410000 | China |
Not provided
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D012559 | Schizophrenia |
| D003865 | Depressive Disorder, Major |
| D000067877 | Autism Spectrum Disorder |
| D001714 | Bipolar Disorder |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D002659 | Child Development Disorders, Pervasive |
Not provided
Not provided
| ID | Term |
|---|---|
| D014150 | Antipsychotic Agents |
| D000928 | Antidepressive Agents |
| ID | Term |
|---|---|
| D014149 | Tranquilizing Agents |
| D002492 | Central Nervous System Depressants |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
10ml peripheral blood
|
| D065886 | Neurodevelopmental Disorders |
| D000068105 | Bipolar and Related Disorders |
| D020164 | Chemical Actions and Uses |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |
| D011619 | Psychotropic Drugs |